Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ruth Perets

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Journal for Immunotherapy of Cancer|November 3, 2022
FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapyToni K Choueiri, Harriet Kluger, Saby George, et al.
Genes & Development|July 13, 2017
PRKCI promotes immune suppression in ovarian cancerSharmistha Sarkar, Christopher A Bristow, Prasenjit Dey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2026
Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid TumorsManish R Sharma, John Powderly, Yasutoshi Kuboki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2024
Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal CancerHans Prenen, Sanjeev Deva, Bhumsuk Keam, et al.
Ebiomedicine|October 12, 2024
Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinomaLoic Verlingue, Antoine Italiano, Hans Prenen, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Journal for Immunotherapy of Cancer|November 3, 2022
FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapyToni K Choueiri, Harriet Kluger, Saby George, et al.
Genes & Development|July 13, 2017
PRKCI promotes immune suppression in ovarian cancerSharmistha Sarkar, Christopher A Bristow, Prasenjit Dey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2026
Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid TumorsManish R Sharma, John Powderly, Yasutoshi Kuboki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2024
Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal CancerHans Prenen, Sanjeev Deva, Bhumsuk Keam, et al.
Ebiomedicine|October 12, 2024
Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinomaLoic Verlingue, Antoine Italiano, Hans Prenen, et al.
Pageof 4